Jump to content

Zeltia

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by All In All In (talk | contribs) at 07:49, 25 July 2022 (History). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Zeltia, S.A.
Company typeSociedad Anónima
BMADZEL
ISINES0184940817
IndustryPharmaceutical
FoundedVigo, Galicia, Spain (August 3, 1939 (1939-08-03))
Defunct2015 (2015)
Headquarters
Madrid
,
Spain
Area served
Worldwide
Key people
José Fernández Sousa-Faro (Chairman)
ProductsPharmaceuticals
RevenueIncrease US$176 million (2009)
Increase (US$46.3) million (2009)
Increase (US$40.3) million (2009)
Total assetsIncrease US$302.9 million (2009)
Total equityDecrease US$59 million (2009)
SubsidiariesPharmaMar, Genómica, Sylentis, Zelnova, Xylazel
Websitewww.zeltia.com
Footnotes / references
[finan 1][history 1]

Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.[history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.[history 3]

History

In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal.[1]

The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.

In 2018 PharmaMar sells Xylazel to the Dutch company AkzoNobel.[2][3]

In 2019 PharmaMar sells Zelnova, the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for 33 million euros.[4]

Subsidiaries

Direct subsidiaries as of 2009 were:[finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.

Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were:[finan 2] Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd.

A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A.[finan 2]

References

  1. ^ "El pueblo que levantó una industria". La Voz de Galicia. August 31, 2015.
  2. ^ "Pharma Mar vende su química gallega Xylazel por 21,8 millones » Galicia" (in Spanish). Retrieved July 25, 2022.
  3. ^ Construcción, Alimarket. "Akzo Nobel compra la fabricante gallega Xylazel - Noticias de Construcción en Alimarket, información económica sectorial". Alimarket.es (in Spanish). Retrieved July 25, 2022.
  4. ^ Ropero, Javier García (August 24, 2020). "Zelnova buscará compras y crecer en el exterior para facturar 100 millones en 2024". Cinco Días (in Spanish). Retrieved July 25, 2022.

Financial

  1. ^ "Zeltia, S.A." (database record). Austin, Texas, United States: Hoover's. Companies. Retrieved May 7, 2011.
  2. ^ a b c "Consolidated Financial Statements as of 31 December 2009". Zeltia. April 16, 2010. Retrieved May 7, 2011.

History

  1. ^ Bueno, María José Sánchez (2008), El proceso innovador y tecnológico: estrategias y apoyo público (Google Books) (in Spanish), Netbiblo, p. 175, ISBN 978-84-9745-240-3, OCLC 434255490, retrieved May 7, 2011
  2. ^ Clark, Todd D. (2007), "Spain", PharmaHandbook: a guide to the international pharmaceutical industry (Google Books) (5 ed.), New Orleans, Louisiana, United States: Value of Insight Consulting, p. 381, ISBN 978-0-9795443-0-9, OCLC 254331162, retrieved May 7, 2011
  3. ^ Jericó, Pilar (2009), "The Price of Fear", No Fear: In Business and In Life (Google Books), Basingstoke, United Kingdom: Palgrave Macmillan, p. 66, ISBN 978-0-230-58038-1, OCLC 636422030, retrieved May 7, 2011